Horizon Pharma (NASDAQ:HZNP)‘s stock had its “buy” rating reaffirmed by investment analysts at Piper Jaffray Cos. in a note issued to investors on Wednesday, American Banking and Market News reports. They currently have a $7.00 price target on the stock. Piper Jaffray Cos.’s price target indicates a potential upside of 17.06% from the stock’s previous close.
Horizon Pharma (NASDAQ:HZNP) traded down 1.32% during mid-day trading on Wednesday, hitting $5.98. The stock had a trading volume of 2,941,275 shares. Horizon Pharma has a 52 week low of $1.97 and a 52 week high of $6.09. The stock has a 50-day moving average of $4.17 and a 200-day moving average of $2.96. The company’s market cap is $393.8 million.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.03) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.22. The company had revenue of $31.50 million for the quarter, compared to the consensus estimate of $18.31 million. During the same quarter last year, the company posted ($0.47) earnings per share. Analysts expect that Horizon Pharma will post $-0.85 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on HZNP. Analysts at Stifel Nicolaus raised their price target on shares of Horizon Pharma from $7.00 to $10.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at JMP Securities raised their price target on shares of Horizon Pharma from $8.00 to $10.00 in a research note to investors on Wednesday. They now have a “market outperform” rating on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Horizon Pharma from $6.50 to $10.00 in a research note to investors on Tuesday. They now have an “outperform” rating on the stock. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $8.60.
Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.